Locher C, Kossowsky J, Koechlin H, et al. - A systematic review and network meta-analysis was conducted to investigate whether prophylactic pharmacologic treatments are more effective than placebo and whether there are differences between drugs regarding efficacy, safety, and acceptability. Researchers searched MEDLINE, Cochrane, Embase, and PsycINFO and published through July 2, 2018. Primary endpoints included efficacy (ie, migraine frequency, number of migraine days, number of headache days, headache frequency, or headache index), safety (ie, treatment discontinuation owing to adverse events), and acceptability (ie, treatment discontinuation for any reason). Researchers included 27 studies involving a total of 2,217 individuals. In pediatric migraine, prophylactic pharmacologic treatments have little evidence to support efficacy. Further study is needed to distinguish factors associated with individual responses to pharmacologic prophylaxis, to investigate variations of migraine attack frequency over time and determine the most clinically relevant length of probable prophylactic treatment, and to recognize nonpharmacologic targets for migraine prophylaxis.